Sections
| Title | Starting Page | Number of Pages |
|---|
| Part of BMI's Industry Report &Forecasts Series | 2 | 4 |
| Executive Summary | 6 | 2 |
| SWOT Analysis | 8 | 4 |
| Pharmaceutical Risk/Reward Ratings | 12 | 3 |
| Rewards | 13 | 1 |
| Risks | 13 | 2 |
| Thailand Market Summary | 15 | 2 |
| Regulatory Regime | 17 | 9 |
| Recent Regulatory Developments | 18 | 1 |
| Regional Harmonisation | 19 | 1 |
| Intellectual Property Regime | 19 | 1 |
| IP Shortcomings | 20 | 1 |
| Counterfeit Drugs | 21 | 1 |
| Compulsory Licensing | 22 | 1 |
| IP Developments | 23 | 1 |
| Pricing And Reimbursement | 24 | 2 |
| Industry Trends And Developments | 26 | 13 |
| Epidemiology | 26 | 1 |
| Communicable Diseases | 27 | 1 |
| Healthcare System | 27 | 2 |
| Healthcare Insurance | 29 | 1 |
| Medical Tourism | 30 | 2 |
| Research And Development (R&D) | 32 | 1 |
| Biosimilars | 33 | 1 |
| Clinical Trials | 34 | 2 |
| Medical Devices | 36 | 1 |
| Developments In The Medical Devices Sector | 37 | 2 |
| Industry Forecast Scenario | 39 | 23 |
| Overall Market Forecast | 39 | 2 |
| Healthcare Market Forecast | 41 | 3 |
| Key Growth Factors Macroeconomic | 44 | 4 |
| Prescription Drug Market Forecast | 48 | 2 |
| Patented Drug Market Forecast | 50 | 2 |
| Generic Drug Market Forecast | 52 | 2 |
| OTC Medicine Market Forecast | 54 | 2 |
| Pharmaceutical Trade Forecast | 56 | 2 |
| Medical Device Market Forecast | 58 | 2 |
| Other Healthcare Data | 60 | 1 |
| Key Risks To BMI s Forecasts | 61 | 1 |
| Competitive Landscape | 62 | 9 |
| Pharmaceutical Industry | 62 | 1 |
| Domestic Pharmaceutical Industry | 63 | 2 |
| Foreign Pharmaceutical Industry | 65 | 1 |
| Recent Pharmaceutical Industry Developments | 66 | 1 |
| Pharmaceutical Wholesale | 67 | 1 |
| Pharmaceutical Retail | 68 | 3 |
| Company Profiles | 71 | 22 |
| Domestic Companies | 71 | 11 |
| Multinational Companies | 82 | 11 |
| Demographic Data | 93 | 4 |
| Glossary | 97 | 2 |
| BMI Methodology | 99 | 1 |
| How We Generate Our Pharmaceutical Industry Forecasts | 99 | 1 |
| Pharmaceuticals Business Environment Ratings | 100 | 3 |
| Risk/Reward Ratings Methodology | 100 | 1 |
| Ratings Overview | 100 | 2 |
| Weighting | 102 | 1 |
| Sources | 102 | 1 |